Neuren's Pipeline Bet Faces Its First Real Regulatory Test

Fund managers built a thesis on Daybue's discount and a free option on NNZ-2591, then a European regulatory setback narrowed the picture

28 Feb 2026 · 4 min read

For Neuren Pharmaceuticals, the story fund managers have been telling since mid-2025 rests on a simple idea: the market is pricing in far less than the company's drug pipeline is worth. Endeavor Asset Management, which rotated out of CSL and into Neuren in February 2025, said in its October 2025 monthly report that the position had gained 53 per cent since the switch, a gap it attributed to Neuren's re-rating potential rather than any single catalyst.

That thesis was first laid out in detail by Seneca Financial Solutions in July 2025, which argued that buying Neuren at the time meant effectively getting its approved rare-disease drug Daybue at a meaningful discount, with a free option attached in the form of NNZ-2591, a second drug then progressing through phase 3 trials. The manager said the stock appeared to be re-rating on no specific news beyond an ongoing share buyback, describing it as a name emerging from a period in the doldrums and moving closer to fair value as the option value on its pipeline asset increased over time.

In essence, at our buy price, we are getting Neuren's Daybue drug for rare diseases at a meaningful discount, plus a free option on its second drug NNZ-2591, which is progressing through phase 3 trials, for free.

— Seneca Financial Solutions, Monthly Report, July 2025

A regulatory setback tests the thesis

That confidence was tested in February 2026, when European regulators indicated that Daybue's active ingredient, trofinetide, was unlikely to be approved for Rett syndrome in Europe, a decision that would limit the drug's addressable sales outside the United States. Endeavor Asset Management, reporting on the same month, said the update weighed on sentiment alongside feedback from the US FDA suggesting a longer development timeline for NNZ-2591. NorthStar Impact Funds described Neuren as weak during the month amid the regulatory uncertainty, even as the company announced an on-market buyback of up to 5 per cent of issued capital, a move it noted without drawing a firm conclusion on what it signalled about management's view of the valuation.

Endeavor Asset Management's February update did point to an offsetting development: partner Acadia Pharmaceuticals provided strong guidance for US sales of trofinetide under the Daybue brand, which the manager said highlighted continued momentum in the product's US rollout even as the European pathway narrowed.

What's next for the pipeline

With the near-term US commercial performance of Daybue holding up and NNZ-2591 still working through a longer regulatory process than some investors had hoped, the questions managers are watching for centre on how much of Neuren's valuation now depends on the US market alone, and whether the FDA's feedback on NNZ-2591 timing proves to be the final word or an early step in an evolving approval pathway.